YIH
PYXS icon

Y-Intercept (HK)’s Pyxis Oncology PYXS Stock Holding History

Y-Intercept (HK)’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133,047
Closed -$146K – 1948
2025
Q2 		$146K Buy
+133,047
New +$150K ﹤0.01% 1502
2024
Q2 		– Sell
-28,053
Closed -$120K – 1815
2024
Q1 		$120K Buy
+28,053
New +$118K 0.01% 1258

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Y-Intercept (HK)'s PYXS Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Pyxis Oncology (PYXS) in Q3 2025, closing a stake of 133,047 shares — an estimated $146K sold.

Y-Intercept (HK) first reported a position in PYXS in Q1 2024 and held it in 2 quarters. The position peaked at $146K in Q2 2025. 73 funds tracked by Wall St. Rank hold PYXS as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Pyxis Oncology position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 133,047 Pyxis Oncology shares in Q3 2025, an estimated $146K.
  • Y-Intercept (HK) first reported a position in Pyxis Oncology in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Pyxis Oncology position peaked at $146K in Q2 2025.
  • 73 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.